Podcasts about lipids

BUFFALO, NY — July 16, 2026 — A new #research paper was #published in Volume 18 of Aging on July 1, 2026, titled “Senescent cells accumulate lipid droplets.” The study was led by first author Noa Rachmian-Cooper and corresponding author Valery Krizhanovsky from the Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel. Cellular senescence is a natural biological process in which damaged or stressed cells permanently stop dividing while remaining metabolically active. Although senescence helps suppress tumor formation and supports normal processes such as tissue repair and development, senescent cells accumulate with age and contribute to chronic inflammation and numerous age-related diseases, including cancer, cardiovascular disease, and Alzheimer's disease. While many of the biological effects of senescent cells have been linked to inflammatory signaling, much less has been understood about the metabolic changes that accompany senescence. In this study, the researchers investigated how cellular metabolism changes during senescence, with a particular focus on lipid metabolism. Using comprehensive metabolic profiling of human fibroblasts, they discovered that senescent cells accumulate high levels of triacylglycerols—the major precursors of lipid droplets—alongside increased glycolytic activity. Additional laboratory experiments confirmed that senescent cells contain significantly more lipid droplets than actively dividing cells. Full press release - https://www.aging-us.com/news-room/senescent-cells-found-to-accumulate-lipid-droplets-across-aging-and-alzheimers-disease DOI - https://doi.org/10.18632/aging.206390 Corresponding author - Valery Krizhanovsky - valery.krizhanovsky@weizmann.ac.il Abstract video - https://www.youtube.com/watch?v=GZbhY3wtGGI Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206390 Keywords - aging, senescence, lipid droplets, metabolism, Alzheimer's disease To learn more about the journal, please visit https://www.Aging-US.com​​ and connect with us on social media at: Bluesky - https://bsky.app/profile/aging-us.bsky.social ResearchGate - https://www.researchgate.net/journal/Aging-1945-4589 X - https://twitter.com/AgingJrnl Facebook - https://www.facebook.com/AgingUS/ Instagram - https://www.instagram.com/agingjrnl/ LinkedIn - https://www.linkedin.com/company/aging/ Reddit - https://www.reddit.com/user/AgingUS/ Pinterest - https://www.pinterest.com/AgingUS/ YouTube - https://www.youtube.com/@Aging-US Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

In this Season 6 Bonus Q&A I'm tackling the following questions from listeners:Why are my lipids suddenly so off? I never had issues when I was younger now every time I get my labs done they seem to be high. I'm a 49 year old woman.No matter what I do I can't seem to feel my glutes much when I train. Any tips? And what are your favorite exercises for building the glutes?I've noticed since my 40s that I get really tapped out when I'm around groups of people. Especially large groups. Even sometimes my coworkers chewing, coughing, making normal people noises drives me insane. To the point I've had to walk out of the room. What going on with me?I go to the bathroom 2 maybe 3x times a week. When I go it's normal but on the days I don't go I don't even have the urge to go. I've tried magnesium, kiwi, greens powders and probiotics nothing works.What's the difference between GERD and heartburn and acid reflux? I have a lot of upper GI tightness and burping.What do you eat?How many times a day do you eat? Do you ever have cheat meals?Enjoy this season 6 bonus!Join me on Instagram! My coaching is for women who are ready to stop chasing quick fixes and start building a body that actually responds through smarter nutrition, strength-focused training, functional health insight, and a more sustainable strategy. You can learn more and apply for coaching at revivewellness.health.Not ready to invest full in coaching? Book a Clarity Consultation!Try Syntrax! To try to the most delicious, gluten free, lactose free "top of the line" whey isolate AND save 15% follow this link. Discount automatically provided at checkout!Want some FREE LMNT? Use this link for a FREE sample pack with any order!Save 10% on...

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/BPW865. CME credit will be available until July 17, 2027.Combining Our Efforts for Patients With High-Risk ASCVD: Applying New Guidelines to Address the Challenge of Lipid Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/BPW865. CME credit will be available until July 17, 2027.Combining Our Efforts for Patients With High-Risk ASCVD: Applying New Guidelines to Address the Challenge of Lipid Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/BPW865. CME credit will be available until July 17, 2027.Combining Our Efforts for Patients With High-Risk ASCVD: Applying New Guidelines to Address the Challenge of Lipid Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/BPW865. CME credit will be available until July 17, 2027.Combining Our Efforts for Patients With High-Risk ASCVD: Applying New Guidelines to Address the Challenge of Lipid Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

What if the word uncurable really just means a doctor has run out of ideas? This episode dares you to question that verdict and discover a functional medicine approach built on gut health, trace minerals, and nervous system repair that has helped many people defy impossible odds and rewrite a hopeless diagnosis into a story of hope.Host Jenn Trepeck welcomes Dr. Aaron Hartman to Salad with a Side of Fries, where he shares how chronic illness recovery starts with the basics everyone overlooks, and why patients in remission from conditions like multiple sclerosis prove healing is possible even when doctors say there is nothing more they can do.What You Will Learn in This Episode:✅ Why the label “incurable” often just means idiopathic (unknown cause) and how functional medicine looks deeper✅ How gut health, sleep, and stress form the foundation of true chronic illness recovery✅ The connection between hypermobility, dysautonomia, mast cell activation, and autoimmune disease✅ Why organ meats, bone broth, and trace minerals support the nervous system and healingThe Salad With a Side of Fries podcast, hosted by Jenn Trepeck, explores real-life wellness and weight-loss topics, debunking myths, misinformation, and flawed science surrounding nutrition and the food industry. Let's dive into real-life wellness and weight loss, including drinking, eating out, and skipping the grocery store.TIMESTAMPS:00:00 Introduction to this episode on functional medicine and rethinking an incurable diagnosis03:47 Dr. Aaron Hartman explains cerebral palsy and his daughter Anna's dire early diagnosis07:17 Why incurable and idiopathic are labels Dr. Hartman refuses to accept and exploring the mast cell activation, hypermobility, autoimmune, gut, and dysautonomia super syndrome15:28 The big three foundations of gut health, stress regulation, and quality sleep for healing21:41 Why trace minerals, organ meats, and bone broth matter for true nutrient-dense nutrition24:38 Practical sleep hygiene tips rooted in circadian rhythm and nervous system regulation28:58 Balancing sugar addiction and dopamine-driven cravings with real food healing habits31:43 How the body's self-healing capacity applies at any age, from childhood through adulthood37:12 Lipid medicine: Using fats to heal your bodyKEY TAKEAWAYS:

Send us Fan MailFerroptosis, an iron-dependent cell death pathway driven by lipid peroxidation; chronoferoptosis, in which chronic stress sensitizes neurons gradually.TOPICS DISCUSSED:Cell Death Pathways: Apoptosis proceeds through regulated steps with surface “eat me” signals that enable non-inflammatory clearance by phagocytes, whereas ferroptosis and related pathways release cellular contents that can amplify local damage and inflammation.Ferroptosis Discovery: Work on glutamate toxicity in neuronal cell lines first identified a glutathione-depletion pathway termed oxytosis; parallel studies in cancer cells renamed and generalized it as ferroptosis to highlight iron's catalytic role.Lipid Peroxidation: Polyunsaturated fatty acids in membranes are oxidized non-enzymatically when ferrous iron reacts with hydrogen peroxide in the Fenton reaction, generating hydroxyl radicals that produce toxic lipid peroxides and reactive carbonyls that modify proteins.GPX4 & Glutathione: Glutathione peroxidase-4 is an enzyme that reduces lipid peroxides within membranes and requires glutathione as cofactor; depletion of either component removes this critical line of defense.Chronoferoptosis: Nine-day treatment of differentiated neuronal cells with chronic iron or glutathione synthesis inhibitor reduced GPX4 protein, raised basal lipid peroxidation, and increased cell death after addition of otherwise sublethal secondary stressors.Protective Compounds: Screening identified flavonoids such as fisetin and sterubin plus synthetic molecules J-147 and CMS-121 that block lipid peroxidation directly or indirectly and, in several cases, also raise glutathione levels.Human Disease Evidence: Postmortem brain tissue from Alzheimer's and Parkinson's patients shows elevated lipid peroxidation markers and altered iron handling in vulnerable regions; similar changes appear in animal models of multiple diseases.Dietary & NRF2 Links: Compounds that activate the NRF2 transcription factor, including sulforaphane from broccoli and certain flavonoids, upregulate antioxidant enzymes including GPX4 and may support long-term cellular resilience.ABOUT THE GUEST: Pamela Maher, PhD is a research professor at the Salk Institute for Biological Studies in La Jolla, California. Her laboratory studies ferroptosis mechanisms in neurodegenerative diseases and works to identify compounds that inhibit iron-dependent lipid peroxidation. Support the showSupport my work:Good Chemistry: Personalized, science-based health consulting. Work with Dr. Nick Jikomes directly.Affiliate Partners: Visit this link to see my affiliate partners and get discounts codes for products & services to support health.For all the ways you can support my efforts.

Broadcast from KSQD, Santa Cruz on 7-02-2026: Dr. Dawn devotes the first half of the show to a nuanced defense of GLP-1 receptor agonists, arguing the polarized debate treats obesity as a moral failure rather than a physiological one. She recounts the "Marilyn Monroe dress" moment that transformed semaglutide from diabetes drug into elite cosmetic tool, and pushes back on the puritanical framing that behavior change must be earned rather than pharmacologically enabled—noting we don't apply this logic to antihypertensives or statins. Dr. Dawn catalogs visceral fat as a genuine endocrine organ producing over 17 hormones, most of which drive self-perpetuating growth: leptin (this satiety hormone at high levels disables it's own brain receptor), IL-6, TNF-alpha (blocks insulin), resistin (increases insulin resistance and inflammation), PAI-2 (blocks clot breakdown, raising cardiovascular risk), retinol-binding protein 4 (impairs muscle glucose uptake), chemerin (recruits macrophages and directs fat to the belly), and visfatin. Only adiponectin declines with rising visceral fat. It improves insulin sensitivity, suppresses hepatic gluconeogenesis, and blocks IL-6 . Dr. Dawn describes GLP-1's neurobiological action: receptors in the hypothalamus, brainstem, hippocampus, and mesolimbic reward system, with the drugs quieting the brain's salience network so food loses its intrusive pull. Taste buds shift, sweet and salty become muted, and reward circuits stop firing on cheat foods—creating a window during which behavioral change becomes possible. Dr. Dawn frames group support through self-determination theory (autonomy, competence, relatedness), arguing GLP-1s create the cognitive bandwidth for behavioral programs to succeed. A Tufts study of patients discontinuing after 10% weight loss found those enrolled in behavioral support programs regained about three times less weight than usual-care controls, outperforming even medically-tailored meal plans. Group engagement doubled the time patients stayed on the medication. A November 2025 Nature study piggybacked on deep brain stimulation research at Penn. Electrodes implanted in the nucleus accumbens of post-bariatric patients recorded low-frequency brain activity surges during food-noise episodes on drug free patients. A third participant who started tirzepatide showed complete silencing of that signature—the first direct electrical confirmation that GLP-1s suppresses compulsive food thoughts in the reward center. RNA sequencing of adipose tissue from 25 obese patients before and after bariatric surgery, compared to 24 lean controls, revealed persistent epigenetic changes even after weight loss. Lipid-associated inflammatory macrophages drop but retain some of their pro-inflammatory epigenetics, explaining the well-known slippery slope back to obesity—and why Dr. Dawn suggests GLP-1s may work best as intermittent tools when behavioral maintenance starts slipping. An emailer asks about long-term smoking versus vaping data. Dr. Dawn notes there is no long-term data yet, but short-term evidence shows e-cigarettes contain nicotine, propylene glycol, reactive oxygen species, and nitrosamines, producing spirometry readings similar to mild COPD in otherwise-healthy vapers. Vaping over a year raises stroke relative risk by 1.62 and nearly doubles MI risk, and combining smoking and vaping produces a multiplicative rather than additive harm. Data on cancer will take decades to emerge. Researchers built a functioning underwater breathing apparatus for cockroaches with electrodes attached to brain and sensory organs allowing remote-controlled direction while preserving natural obstacle-navigation autonomy. The 10mm × 10mm sponge-based oxygen tank uses magnesium dioxide catalyzing hydrogen peroxide breakdown, delivering oxygen through silicone tubes to the roach's spiracles for up to three hours underwater. Deployemenet will improve search-and-rescue in flooded and collapsed structures where dogs cannot reach. A Science Advances paper from Yong Lin Kong's lab at Rice University describes 3D-printing electronic circuits directly onto living tissue. Researchers achieved microwave-focused annealing at sub-200-micrometer resolution. By selectively heating only conductive ink particles (copper, silver, gold) without damaging surrounding tissue, the technique enables printing circuits onto 3D-printed heart valves, tracheas, and ear scaffolds, potentially creating combined graft-and-sensor implants, ingestible diagnostic devices, and perhaps even decorative electronic tattoos. A single-shot reformulation of zanamivir (originally the inhaled flu drug Relenza) provided 76.1% flu protection in a 5,000-participant trial—far exceeding the roughly 40-45% offered by annual flu vaccines. Because zanamivir targets neuraminidase in a way that inactivates it if the virus tries to mutate around the drug, trapping newly-made viral copies inside their host cells, this approach works across all flu strains and could bypass the annual guessing game of trivalent vaccine formulation.

CME credits: 1.00 Valid until: 30-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/gaps-global-implementation-lipid-guidelines/54672/ A new modular CME-accredited program designed to support clinicians in translating evolving lipid guidelines into everyday practice. Delivered as a 60-minute webcast, divided into chapters for convenience, it integrates U.S. and international perspectives and focuses on equitable cardiovascular care. The course highlights women-specific cardiovascular risk modifiers, including reproductive and hormonal factors that are often under-recognized in risk assessment. It also emphasizes practical, multidisciplinary approaches to improving lipid management outcomes across diverse health systems. =

Send us Fan MailNearly a decade after the last major cholesterol guidelines were released, the new 2026 Multi-Specialty Lipid Guidelines introduce significant changes in how cardiovascular risk is assessed and managed. In this episode, Albert Lopez, DO, FACP, FASPC, explains why LDL cholesterol treatment goals have returned, how newer markers such as ApoB and Lipoprotein(a) are reshaping risk assessment, and why earlier, more aggressive treatment may help reduce the world's leading cause of death, cardiovascular disease.Dr. Al Lopez, DO,  discusses the role of statins, non-HDL cholesterol, triglycerides, genetic cholesterol disorders, screening recommendations for children and older adults, and the importance of a team-based approach to prevention. Whether you're a healthcare professional or someone interested in protecting your heart health, this episode provides a practical overview of the latest evidence-based recommendations for preventing heart disease.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Show notes at pharmacyjoe.com/episode1139 In this episode, I'll discuss the dosing of lipid rescue therapy for LAST vs enteral drug toxicity.

In Part 2 of this special two-part series on genetic lipid disorders, Susan Robbins welcomes back renowned lipidologist Dr. Tom Dayspring for an eye-opening discussion on Lipoprotein(a), often written as Lp(a), one of the most common yet overlooked genetic cardiovascular risk factors in the world. While many people focus on standard cholesterol numbers, Dr. Dayspring explains why Lp(a) deserves far more attention and why major cardiovascular organizations now recommend that every person be tested at least once in their lifetime.Together, Susan and Dr. Dayspring break down the science behind Lp(a), how it differs from traditional cholesterol markers, and why elevated levels can significantly increase the risk of atherosclerosis, stroke, and aortic valve disease. They discuss the role genetics play in determining Lp(a) levels, why lifestyle changes remain important even when they do not directly lower Lp(a), and how advanced testing can provide a more complete picture of cardiovascular risk.This conversation also tackles common misconceptions surrounding cholesterol, statins, and influencer-driven health advice. Dr. Dayspring shares practical guidance on what to do if you discover you have elevated Lp(a), how to advocate for yourself within the healthcare system, and why understanding your unique biology is essential for protecting long-term health.In this episode:What Lipoprotein(a) or Lp(a) is and why it mattersWhy Lp(a) is one of the most common genetic lipid disorders worldwideThe connection between elevated Lp(a), heart disease, stroke, and aortic valve diseaseWhy every person should consider being tested for Lp(a) at least onceHow genetics determine Lp(a) levels throughout lifeThe difference between Lp(a), LDL cholesterol, and ApoBWhy standard cholesterol testing may miss important cardiovascular risk factorsThe role of oxidized phospholipids in cardiovascular diseaseIf you've ever been told your cholesterol is "normal" but still have a family history of heart disease, stroke, or unexplained cardiovascular events, this episode offers critical information that could help you ask better questions, pursue the right testing, and become a stronger advocate for your own health.Learn more about Dr. Tom Dayspring on the website shownotes!https://healthyawakening.co/2026/06/15/episode128/RESOURCES:Connect with Dr. Tom DayspringX: https://x.com/drlipidhttps://familyheart.org/https://healthyawakening.co/2026/06/15/episode128/Connect with Susan: https://healthyawakening.co/Visit the website: healthyawakening.co/podcastFind listening links here: https://healthyawakening.co/linksP.S. Want reminders about episodes? Sign up for our newsletter, you can find the link on our podcast page! https://healthyawakening.co/podcast

Dr. Hoffman continues his conversation with Dr. Garth Nicolson, Founder, President, Chief Scientific Officer, and Emeritus Research Professor of Molecular Pathology at the Institute for Molecular Medicine in Huntington Beach, California, and Research Advisor for Nutritional Therapeutics.

Dr. Garth Nicolson, Founder, President, Chief Scientific Officer, and Emeritus Research Professor of Molecular Pathology at the Institute for Molecular Medicine in Huntington Beach, California, and Research Advisor for Nutritional Therapeutics, explains how membrane damage from free radicals and loss of mitochondrial transmembrane potential contribute to declining energy with age, noting studies in older adults showing improved energy output, fatigue, cognition, mood, and activity after NTFactor lipids, a protected phospholipid supplement balanced toward mitochondrial lipid composition. He describes evidence of lipid delivery using fluorescent-tagged lipids in sperm, with improved motility, and discusses applications including wound healing in veterans, removal of hydrophobic toxins via a concentration-driven “conveyor belt” process, and improved transport of nutrients like CoQ10. He details articles on normal aging, menopause-related changes supported by membranes, dementia risk linked to hearing loss, and rat studies showing delayed hearing loss with NTFactor, and mentions research on EMF sensitivity and planned schizophrenia trials.

Dr. Paulo Porto de Melo é uma autoridade máxima e brutal quando o assunto é a máquina mais complexa do universo. Ex-major do Exército por 19 anos e pioneiro na introdução da neurocirurgia robótica no Brasil , ele carrega o privilégio de ter tocado e operado mais de 10.000 cérebros humanos. Neste episódio, ele deixa a linguagem corporativa morna de lado para escancarar os segredos de bastidores que determinam quem terá uma mente brilhante ou quem sofrerá um colapso cognitivo total nas próximas décadas. Prepare-se para descobrir a verdade oculta sobre a demência que começa a destruir seus neurônios 20 anos antes do primeiro sintoma aparecer. Dr. Paulo revela o perigo invisível por trás dos remédios para dormir , o impacto destrutivo da cafeína no cérebro , a farsa do açúcar que causa o "Diabetes Tipo 3" , e uma descoberta científica chocante: a comunicação quântica dos neurônios através de fótons de luz. Uma verdadeira aula de sobrevivência e alta performance biológica que vai redefinir o seu futuro.Patrocinador:Clinica RUV - Harmonização que respeita quem você é.https://www.instagram.com/dra.najlavicentini/Disponivel Também no Youtube:https://youtu.be/cOwuA8H2SLc00:00:00 - O perigo ético da Neuralink e os backdoors chips cerebrais. 00:05:30 - Como prevenir 45% das demências e blindar sua coluna contra hérnias. 00:08:20 - Diabetes Tipo 3: A falência energética e a fome celular dos neurônios. 00:14:00 - O chocante Estudo das Freiras: Caminhos alternativos e redundância cognitiva. 00:18:10 - Lipidômica: O teste definitivo da ponta do dedo para equilibrar sua membrana celular. 00:23:50 - O erro do prato brasileiro: A ordem que você come altera sua glicose em 70%. 00:25:20 - Jejun intermitente, autofagia e o sinal de qualidade para o corpo. 00:34:00 - A verdadeira arquitetura do sono e a redução de 60% dos neurônios. 00:36:10 - Por que os remédios para dormir são uma farsa que te deixa cansado. 00:41:30 - Cafeína e o receptor de Adenosina: O soco no queixo da sua energia. 00:47:40 - O erro fatal de tomar café imediatamente após acordar. 00:53:00 - O piano genético e como a atividade física afasta doenças crônicas. 01:00:00 - Cortisol, privação de sono militar e a técnica limite da CIA. 01:13:30 - Cérebro Quântico: A descoberta dos fótons de luz entre neurônios. 01:17:20 - O caso real do tumor que era um abscesso: O diagnóstico pelo cheiro. 01:20:00 - AVC Isquêmico vs Hemorrágico e os sinais de alerta definitivos. 01:52:00 - Como os restaurantes usam a neurociência e luzes amarelas para hackear sua fome. Siga a Dr. Paulo no Instagram:⁠https://www.instagram.com/ppmelo/Nos Siga:Marcelo Toledo: ⁠https://www.instagram.com/marcelotoledoInstagram: ⁠https://www.instagram.com/excepcionaispodcastTikTok: ⁠https://www.tiktok.com/@excepcionaispodcast

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Tom Dayspring is a world-renowned lipidologist and one of the most thoughtful teachers in the field of lipid metabolism. In this episode, Tom returns to The Drive for a deep dive into the relationship between lipids and brain health, beginning with the fundamentals of cholesterol transport before exploring why the brain's cholesterol system operates almost entirely independently from the rest of the body. Tom examines the roles of apoB, apoA-I, and especially apoE in cholesterol homeostasis, discusses how APOE genotype influences Alzheimer's disease risk, and unpacks the complex links between cholesterol metabolism, amyloid, and tau pathology. He also reviews what is currently known—and still uncertain—about the effects of statins, ezetimibe, omega-3 fatty acids, and emerging CETP inhibitors on brain health and neurodegenerative disease risk. Although highly technical, this conversation provides an essential framework for understanding the nuanced relationship between lipid-lowering therapies, cardiovascular disease prevention, and neurodegenerative diseases in an area often clouded by misinformation. We discuss: The fundamentals of cholesterol transport in the body, and how peripheral cholesterol metabolism differs from cholesterol handling in the brain [2:45]; How cholesterol is transported through plasma and stored within cells, and why lowering LDL cholesterol does not deplete the body or brain of cholesterol [11:45]; How apoB particles drive atherosclerosis, why lowering lipids matters, and the factors that influence individual cardiovascular risk [20:00]; How the brain produces and transports its own cholesterol using apoE lipoproteins independently of circulating cholesterol and apoB-containing lipoproteins [29:00]; How apoB structure influences LDL receptor binding and LDL clearance [39:00]; How neurons acquire cholesterol from apoE-containing lipoproteins and why desmosterol serves as a unique marker of cholesterol synthesis in the brain [41:45]; The difference between the APOE gene and the apoE protein, the major APOE genotypes found in humans, and how APOE4 influences Alzheimer's disease risk [48:45]; HDL function beyond cholesterol: immune function, protein cargo, and communication with the brain [53:30]; How APOE4-associated defects in brain cholesterol transport may promote Alzheimer's disease: amyloid production, neuronal cholesterol homeostasis, and cholesterol clearance [58:00]; Statins and brain health: reviewing the evidence of the potential impact of statins on cognition and Alzheimer's disease risk [1:09:00]; Desmosterol and 24S-hydroxycholesterol as biomarkers of brain cholesterol metabolism and statin effects [1:17:15]; Possible cognitive benefits of ezetimibe beyond lowering apoB [1:19:30]; EPA, DHA, and the evidence for omega-3 fatty acids in brain health [1:23:15]; Obicetrapib: an emerging CETP inhibitor with potential implications for both cardiovascular and brain health [1:31:00]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

In this episode of Everyday Epigenetics: Raw. Real. Relatable., Susan Robbins is joined by renowned expert lipidologist Dr. Tom Dayspring for Part 1 of a special two-part series on genetically driven lipid disorders. Together, they explore phytosterolemia (formerly known as sitosterolemia), a little-known but potentially serious genetic condition that affects how the body absorbs and processes plant sterols. While often overlooked in conventional healthcare, this disorder can contribute to elevated cholesterol markers, cardiovascular risk, xanthomas, kidney issues, and other health concerns when left undetected.Dr. Dayspring breaks down the complex science of cholesterol absorption, plant sterols, and the ABCG5 and ABCG8 genes in a way that is easy to understand. Susan shares what she has observed through years of genetic testing and coaching, including how frequently she is seeing these gene variants appear in practice and why many people are being missed by standard testing. This conversation highlights the importance of personalized medicine, advanced lipid testing, and understanding the unique ways genetics can influence long-term health outcomes.In this episode:What phytosterolemia is and why it is often missedThe difference between cholesterol and plant sterolsHow the ABCG5 and ABCG8 genes regulate sterol absorptionWhy some people absorb significantly more cholesterol than othersThe connection between plant sterol hyper-absorption and cardiovascular disease riskWhy standard cholesterol testing may miss important cluesThe role of sitosterol and campesterol testingHow phytosterols can impact cell membranes, kidneys, joints, blood cells, and other tissuesThe difference between heterozygous and homozygous loss-of-function gene variantsWhy many patients are told their cholesterol is "fine" when deeper issues may existThe importance of ApoB, non-HDL cholesterol, and advanced lipid testingWhy some cholesterol-lowering therapies work better than others depending on geneticsHow lifestyle, nutrition, and personalized interventions can support lipid healthWhen to consider working with a lipid specialistIf you have a family history of heart disease, unexplained cholesterol elevations, or have been told your numbers are "normal" despite ongoing concerns, or if use of statins hasn't helped yu, this episode offers valuable insight into a genetic factor that is rarely discussed but can have a significant impact on long-term health.Learn more about Dr. Tom Dayspring on the website shownotes!https://healthyawakening.co/2026/06/08/episode127/RESOURCES:Connect with Dr. Tom DayspringX: https://x.com/drlipidhttps://healthyawakening.co/2026/06/08/episode127/Connect with Susan: https://healthyawakening.co/Visit the website: healthyawakening.co/podcastFind listening links here: https://healthyawakening.co/linksP.S. Want reminders about episodes? Sign up for our newsletter, you can find the link on our podcast page! https://healthyawakening.co/podcast

We've reached the final episode of our dyslipidemia series! In this episode, we explore several additional lipid-lowering therapies, including fibrates, niacin, omega-3 fatty acids, and Evkeeza (evinacumab). Join me as we discuss how these agents fit into the management of dyslipidemia and wrap up our journey through the world of cholesterol and lipid management. Thank you for listening!

Welcome to this week's Midlife Minute. Today, I'm focusing on all the questions I received about gallbladder health, including HRT-provoking symptoms, supplements that improve gallbladder health, and evidence-based food interventions. IN THIS EPISODE, YOU WILL LEARN: Why the risk of gallstones and gallbladder inflammation increases during the menopause transition How estrogen and progesterone HRT have different effects on gallbladder functioning The differences in risk between transdermal and oral HRT How the progesterone in HRT can cause gallbladder issues in some women What TUDCA is, and how it supports gallbladder health The value of TUDCA for women who have had their gallbladders removed How various nutrients and supplements support bile flow and gallbladder health What can contribute to gallstone formation Connect with Cynthia Thurlow   Follow on X, Instagram & LinkedIn Check out Cynthia's website. Submit your questions to support@cynthiathurlow.com  Join other like-minded women in a supportive, nurturing community: The Midlife Pause/Cynthia Thurlow.  Purchase Cynthia's book, The Menopause Gut. Cynthia's Intermittent Fasting Transformation Book The Midlife Pause Supplement Line Gallbladder Research: Cabrera D, Arab JP, Arrese M. UDCA, NorUDCA, and TUDCA in liver diseases: a review of their mechanisms of action and clinical applications. Seminars in Liver Disease. 2019;39(4):397–404. doi:10.1055/s-0039-1696799  Vang S, Longley K, Steer CJ, Low WC. The unexpected uses of urso- and tauroursodeoxycholic acid in the treatment of non-liver diseases. Global Advances in Health and Medicine. 2014;3(3):58–69. doi:10.7453/gahmj.2014.017  Bai M, Yang L, Liao H, et al. Tauroursodeoxycholic acid improves nonalcoholic fatty liver disease by regulating gut microbiota and bile acid metabolism. Journal of Agricultural and Food Chemistry. 2024;72(41):22655–22668. doi:10.1021/acs.jafc.4c04630  Simon JA, Hudes ES. Relation of serum ascorbic acid to serum vitamin B12, serum ferritin, and kidney stones in US adults. *Archives of Internal Medicine.*1999;159(6):619–624. doi:10.1001/archinte.159.6.619  Walcher T, Haenle MM, Kron M, et al. Vitamin C supplement use may protect against gallstones: an observational study on a randomly selected population. BMC Gastroenterology. 2009;9:74. doi:10.1186/1471-230X-9-74  Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Long-term intake of dietary fiber and decreased risk of cholecystectomy in women. American Journal of Gastroenterology. 2004;99(7):1364–1370. doi:10.1111/j.1572-0241.2004.30281.x  Leitzmann MF, Stampfer MJ, Willett WC, Spiegelman D, Colditz GA, Giovannucci EL. Coffee intake is associated with lower risk of symptomatic gallstone disease in women. Gastroenterology. 2002;123(6):1823–1830. doi:10.1053/gast.2002.37085  Moerman CJ, Smeets FW, Kromhout D. Dietary risk factors for clinically diagnosed gallstones in middle-aged men — a 25-year follow-up study. Annals of Epidemiology. 1994;4(3):248–254. doi:10.1016/1047-2797(94)90099-x Association between dietary magnesium intake and gallstones: the mediating role of atherogenic index of plasma. Lipids in Health and Disease. 2024;23(1):82. doi:10.1186/s12944-024-02074-4  Pitt HA, Doty JE, Murphy MM, Schwarz MB. Progesterone alters biliary flow dynamics. Annals of Surgery. 1999;229(2):205–209. doi:10.1097/00000658-199902000-00008

A breakthrough in inflammatory support has arrived in the natural health market. PEA, which stands for palmitoylethanolamide, is a naturally occurring fatty acid derivative made in the body and found in small amounts in foods. Several human studies have demonstrated that PEA has broad- spectrum pain-relieving properties, anti-inflammatory effects, and nerve protection.To help us unpack all the research and studies we have Dr. Stengler joining us today.In addition to authoring 30 books on health and several best-sellers such as “The Natural Physician's Healing Therapies,” “Prescription for Natural Cures,” “Prescription for Drug Alternatives,” and “Outside the Box Cancer Therapies,” Dr. Stengler has been published in several peer-reviewed medical journals such as The International Journal of Family & Community Medicine, Endocrinology & Metabolism International Journal, and Journal of Nutritional Health & Food Engineering.Dr. Stengler's, NMD. The newest book is called, The Holistic Guide to Gut Health. A comprehensive yet accessible approach to healing leaky gut and the many uncomfortable symptoms it causes. Dr Stengler is also the founder of The Stengler Center for Integrative Medicine.Talking Points:Palmitoylethanolamide (PEA), is a naturally occurring fatty acid derivative made in the body and found in small amounts in foods.PEA was first discovered in 1957 by scientists at Merck Sharp & Dohme, who isolated it from egg yolk, peanut meal, and soy lecithin. They found that PEA had anti-inflammatory properties in guinea pigs.However, PEA's role as a potential therapeutic agent was not widely recognized until 1993, when Rita Levi-Montalcini and her colleagues published research that suggested PEA has anti-inflammatory properties. Levi-Montalcini's group termed PEA an autocoid local injury antagonist (ALIA), and suggested that it acts locally to counteract injury.Multiple studies have demonstrated that PEA improves all sorts of pain. For example, a 2023 analysis of 11 studies found that PEA improved pain of various conditions, including muscle and joints, nerves, gynecological, and digestive. In terms of joint pain, a high-quality study demonstrated that PEA significantly reduced adult joint pain compared to placebo. Moreover, 8 clinical trials demonstrated that PEA was effective for low back pain, sciatica, and carpal tunnel syndrome. Even migraine headache pain was shown in published research to be improved with PEA.Lipid mediators help to balance the immune, nervous, and endocrine systems, affecting pain pathways related to inflammation. But unfortunately, due to changing diets, many of us do not get the nutrition and activity we need to make enough PEA ourselves.Supplemental PEA, by Levagen+ is properly formulated for optimal bioavailability, 75% more bioavailable to cell receptors than dietary forms. Levagen+ liposomal delivery of PEA has been clinically studied and shows benefits in joint pain, nerve pain, migraine, infections, sleep, and cognitive function.Learn more about Dr. Mark Stengler, NMDLearn more about Emerald Labs PEA+ Levagen Use the code: Forever and get 20% off your order.

Join us as we review recent articles and news featured in The DIGEST, including updated lipid guidelines, GLP1 agonists holds and procedures, the newest drug in pancreatic cancer, and discontinuing thyroid supplementation. Fill your brain hole with a delicious stack of hotcakes! Featuring Drs. Nora Taranto (@norataranto), Laura Glick (@lauraglick) and Matt Watto (@doctorwatto).Claim free CME for this episode at curbsiders.vcuhealth.org!Episodes | Subscribe | Spotify | Swag! |Mailing List | Contact | CME!Credits Written and Hosted by: Nora Taranto MD MSCE, Laura Glick MD,  Matthew Watto MD, FACP Cover Art:  Nora Taranto MD MSCE Reviewers: Emi Okamoto MD  Technical Production: Pod Paste Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Show Segments Intro and pun   Lipid Management Guidelines Overview  Emerging Treatments in Oncology  Press Release on a new KRAS Inhibitor for Pancreatic Cancer  Perioperative Considerations for GLP-1 Use  Deprescribing Levothyroxine in Older Adults Sponsor: Panacea FinancialIf you're about to make the leap into  residency and feeling the financial pressure of that transition, visit  PanaceaFinancial.com/curbsiders today. Sponsor: UpToDatefor a limited time, get 10% off UpToDate packages with code CURB10. Visit store.uptodate.com to save on your annual or longer personal UpToDate subscription today. 

For more information and support, join us at https://thecirsgroup.com Jacie and Barbara cover Phase Two (part two of five) of the Shoemaker Protocol for CIRS, focusing on foundational steps before starting binders:  Lipid replacement therapy (primarily fish oil) to lower inflammation and help prevent common binder side effects like fatigue, constipation, and overall dryness, with Shoemaker-recommended omega-3 dosing (EPA 2,400 mg and DHA 1,800 mg daily) and cautions about blood-thinning;  Limbic retraining to address errant threat signals from chronic illness, with nuance that intensive programs can be too difficult early on and may work better once out of exposure and/or on binders, while also warning against symptom suppression without addressing root causes;  And the critical priority of getting out of exposure through testing (dust tests for mold, endotoxins, and actinos), remediation or moving, and exploring hidden, internal exposures that can cause plateaus or backslides in your health. Be sure to subscribe so you don't miss the next episode, all about Phase Three, removing the toxic burden! For more information and support, join us at https://thecirsgroup.com TIMESTAMPS 00:00 Phase Two of the Shoemaker Protocol 01:25 Why this foundational phase matters 02:54 What is Lipid Replacement? and why is it important? 06:17 Fish Oil / lipid dosing tips 08:04 Limbic Retraining explained 10:51 When Limbic Retraining backfires 14:23 Hyperreactivity Catch-22 18:25 Get out of exposure 20:42 Hidden exposures and healing stalls 22:27 Key takeaways and next phase 24:08 Wrap up and resources For more information and support, join us at https://thecirsgroup.com Check out these episodes mentioned in this episode: Interview with Michael Schrantz about remediation: https://youtu.be/_BEwFVdpRcY?si=mzNeGslwGjaYhWqi Interview with Bill Weber about testing your home: https://youtu.be/RlKjTqVAeNU?si=Eymfvcdk4G6kzylV Interview with Kendra Seymour on choosing a remediator or IEP: https://youtu.be/zmt9e42LLac?si=cTTvunobvEt8YL_n Dust testing 101: https://youtu.be/nRrZs7xbXcc?si=55oXFRCV5kO_p0JD Endotoxin episode: https://youtu.be/O0iKndNzfYA?si=X-iX1NoRO2U7U-QV Actinos episode part one: https://youtu.be/yf9EoTbyAEo?si=d2KUSzNpX2cs0DKE and Part two: https://youtu.be/2rCXhUP6dbY?si=wDHiSy58Vw5fZ5fa Order Jacie's book! The 30 Day Carnivore Bootcamp: https://a.co/d/7MgHrRs The CIRS Group: Support Community: https://thecirsgroup.com Instagram: https://www.instagram.com/thecirsgroup/ Find Jacie for carnivore, lifestyle and limbic resources: Jacie's book on the Carnivore diet!  https://a.co/d/8ZKCqz0 Instagram: https://www.instagram.com/ladycarnivory YouTube: https://www.youtube.com/@LadyCarnivory Blog: https://www.ladycarnivory.com/ Find Barbara for business/finance tips and coaching: Website: https://www.actlikebarbara.com/ Instagram: https://www.instagram.com/actlikebarbara/ YouTube: https://www.youtube.com/@actlikebarbara Jacie is a Shoemaker certified Proficiency Partner, NASM certified nutrition coach, author, and carnivore recipe developer determined to share the life changing information of carnivore and CIRS to anyone who will listen. Barbara is a business and fitness coach, CIRS and ADHD advocate, writer, speaker, and a big fan of health and freedom. Together, they co-founded The CIRS Group, an online support community to help people that are struggling with their CIRS diagnosis and treatment.

Welcome to the 35th episode of The Brain Podcast - the official podcast of the journals Brain and Brain Communications.  This episode features a discussion with first author Dr Laetitia Marcadet and senior author Chantelle F Sephton of the Brain article entitled: Targeting lipid droplets in FUS-linked amyotrophic lateral sclerosis mitigates neuronal and astrocytic lipotoxicity. We discuss the interest concept of abnormal cellular energy metabolism in amyotrophic lateral sclerosis and, more broadly, across other neurodegenerative and neurological conditions. The authors outline their combined model of neuronal and, more uniquely, astrocytic compartments to identify response to lipid droplet targeting. Check out the full article on the Brain website as part of the Feb 2026 issue: https://doi.org/10.1093/brain/awaf404 This episode was co-hosted, edited and produced by Roberto Bellanti and Andreas Thermisticleous, co-produced by Xin You Tai and Antonia Johnston, original music by Ammar Al-Chalabi.

A breakthrough in inflammatory support has arrived in the natural health market. PEA, which stands for palmitoylethanolamide, is a naturally occurring fatty acid derivative made in the body and found in small amounts in foods. Several human studies have demonstrated that PEA has broad- spectrum pain-relieving properties, anti-inflammatory effects, and nerve protection.To help us unpack all the research and studies we have Dr. Stengler joining us today.In addition to authoring 30 books on health and several best-sellers such as “The Natural Physician's Healing Therapies,” “Prescription for Natural Cures,” “Prescription for Drug Alternatives,” and “Outside the Box Cancer Therapies,” Dr. Stengler has been published in several peer-reviewed medical journals such as The International Journal of Family & Community Medicine, Endocrinology & Metabolism International Journal, and Journal of Nutritional Health & Food Engineering.Dr. Stengler's, NMD. The newest book is called, The Holistic Guide to Gut Health. A comprehensive yet accessible approach to healing leaky gut and the many uncomfortable symptoms it causes. Dr Stengler is also the founder of The Stengler Center for Integrative Medicine.Talking Points:Palmitoylethanolamide (PEA), is a naturally occurring fatty acid derivative made in the body and found in small amounts in foods.PEA was first discovered in 1957 by scientists at Merck Sharp & Dohme, who isolated it from egg yolk, peanut meal, and soy lecithin. They found that PEA had anti-inflammatory properties in guinea pigs.However, PEA's role as a potential therapeutic agent was not widely recognized until 1993, when Rita Levi-Montalcini and her colleagues published research that suggested PEA has anti-inflammatory properties. Levi-Montalcini's group termed PEA an autocoid local injury antagonist (ALIA), and suggested that it acts locally to counteract injury.Multiple studies have demonstrated that PEA improves all sorts of pain. For example, a 2023 analysis of 11 studies found that PEA improved pain of various conditions, including muscle and joints, nerves, gynecological, and digestive. In terms of joint pain, a high-quality study demonstrated that PEA significantly reduced adult joint pain compared to placebo. Moreover, 8 clinical trials demonstrated that PEA was effective for low back pain, sciatica, and carpal tunnel syndrome. Even migraine headache pain was shown in published research to be improved with PEA.Lipid mediators help to balance the immune, nervous, and endocrine systems, affecting pain pathways related to inflammation. But unfortunately, due to changing diets, many of us do not get the nutrition and activity we need to make enough PEA ourselves.Supplemental PEA, by Levagen+ is properly formulated for optimal bioavailability, 75% more bioavailable to cell receptors than dietary forms. Levagen+ liposomal delivery of PEA has been clinically studied and shows benefits in joint pain, nerve pain, migraine, infections, sleep, and cognitive function.Learn more about Dr. Mark Stengler, NMDLearn more about Emerald Labs PEA+ Levagen Use the code: Forever and get 20% off your order.

Editor's Summary by Linda Brubaker, MD, and Preeti Malani, MD, MSJ, Deputy Editors of JAMA, the Journal of the American Medical Association, for articles published from April 4-10, 2026.

We discuss this ominous complication of providing local anesthesia. Hosts: Elaine Jonas, MD Brian Gilberti, MD https://media.blubrry.com/coreem/content.blubrry.com/coreem/LAST.mp3 Download Leave a Comment Tags: Critical Care, Toxicology Show Notes I. Pathophysiology & Mechanisms Definition: Systemic toxicity secondary to local anesthetic (LA) via accidental intravascular injection or excessive systemic absorption. Threshold: Occurs when plasma concentration exceeds the safety threshold for cardiac and neural tissue. Agent Profile: Bupivacaine (High Risk) Highly lipophilic with high protein binding. “Fast-on, Slow-off” Kinetics: Strong Na+ channel binding with extremely slow dissociation during diastole. Myocardial Depression: Direct inhibition of Ca2+ release from the sarcoplasmic reticulum, impairing contractility. Low CC:CNS Ratio: The dose required for cardiac collapse is very close to the dose that triggers seizures (narrow safety margin). Contributing Factors: Acidosis/Hypercapnia: Increases the fraction of free drug and promotes ion trapping in the brain/heart; shifts the LA-binding curve toward higher toxicity. Hypoxemia: Exacerbates myocardial depression and lowers seizure threshold. II. Risk Assessment & Prevention Patient-Specific Risk Factors Extremes of Age: Neonates (low α-1-acid glycoprotein) and elderly (reduced clearance). Body Composition: Low muscle mass/frailty (decreased volume of distribution). Organ Dysfunction: Hepatic: Reduced metabolism of amide LAs. Renal: Accumulation of metabolites; risk of metabolic acidosis lowering seizure threshold. Cardiac: Reduced cardiac output slows hepatic delivery/clearance; heart failure patients are more sensitive to Na+ channel blockade. Pregnancy: Increased sensitivity to cardiotoxicity. Procedural Risk Factors Vascularity of Site (Highest to Lowest Risk): Intercostal blocks (highest absorption rate). Caudal/Epidural. Interfascial plane blocks (e.g., TAP block). Psoas compartment/Sciatic. Brachial plexus. Technique: Large volume infiltration, lack of ultrasound, lack of incremental injection. Prevention Mandates Weight-Based Dosing: Lidocaine (Plain): Max 4.5 mg/kg. Lidocaine (with Epi): Max 7 mg/kg. Bupivacaine: Max 2.5–3 mg/kg. Incremental Injection: 3–5 mL aliquots with frequent aspiration. Intravascular Marker: Use Epinephrine (1:200,000) to detect accidental IV placement (HR increase >10 bpmor SBP increase >15 mmHg). III. Clinical Presentation Neurologic Phase (Early to Late) Subjective: Metallic taste, tinnitus, circumoral numbness/tingling. Objective: Visual disturbances, agitation, confusion, tremors. Critical: Generalized tonic-clonic seizures, rapid progression to CNS depression, coma, and apnea. Note: Early phases are often masked in patients receiving midazolam or propofol. Cardiovascular Phase Initial: Hypertension and tachycardia (if epi used) or transient stimulatory phase. Conduction Defects: PR prolongation, QRS widening (classic sign), bundle branch blocks. Dysrhythmias: Bradycardia (most common), VT/VF, PEA, asystole. Contractility: Profound, refractory hypotension and cardiogenic shock. IV. Immediate Management Algorithm Goal: Prevent hypoxia/acidosis and sequester the toxin. 1. Initial Actions Stop Injection: Immediately halt all LA administration. Call for Help: Specify “LAST Protocol” and “Intralipid Kit.” Airway Management: 100% O2​. Hyperventilate slightly if needed to counter respiratory acidosis. Low threshold for intubation (hypoxia/acidosis rapidly worsen LAST). 2. Seizure Control First-line: Benzodiazepines (e.g., Midazolam). Avoid: Propofol if hemodynamically unstable (exacerbates cardiac depression). Neuromuscular Blockers: May be needed for ventilation, but remember they do not stop CNS seizure activity. 3. Lipid Emulsion Therapy 20% Indications: Start at first sign of serious toxicity (airway compromise, seizures, or CV instability). Bolus: 1.5 mL/kg IV over 1 minute. Infusion: 0.25 mL/kg/min immediately following bolus. If Instability Persists: Repeat bolus (up to 2 times). Increase infusion to 0.5 mL/kg/min. Upper Limit: ≈12 mL/kg total dose. 4. Modified ACLS Epinephrine: Use low doses (

Dave Feldman, a software engineer turned citizen scientist, went on a ketogenic diet and watched his LDL cholesterol spike dramatically while his family members on the same diet saw no such change. Unable to get cardiologists or lipidologists to study the phenomenon, he built a public charity from scratch, crowdfunded the research, and designed the Keto CTA study — enrolling 100 metabolically healthy people with very high LDL and scanning their coronary arteries with CT angiograms at baseline and one year later. He filmed the entire process. The result is the documentary The Cholesterol Code.The findings were notable, but the story became more complicated when the AI-assisted plaque analysis from the company Cleerly produced results Feldman considered statistically anomalous — including zero regressors across 99 participants, and greater plaque progression in people with a calcium score of zero than in those with a positive score, which contradicts established research. Dave Feldman Contact InfoThe Cholesterol Code Movie: https://cholesterolcodemovie.com/Citizen Science Foundation Website: https://CitizenScienceFoundation.org: Cholesterol Code Website: https://cholesterolcode.com/Send Dr. Ovadia a Text Message. (If you want a response, you must include your contact information.) Dr. Ovadia cannot respond here. To contact his team, please send an email to team@ifixhearts.com Pre-Order Stay Off My Kitchen Table at Amazon. Like what you hear? Head over to IFixHearts.com/book to grab a copy of my book, Stay Off My Operating Table. Ready to go deeper? Talk to someone from my team at IFixHearts.com/talk.Stay Off My Operating Table on X:   Dr. Ovadia: @iFixHeartsJack Heald: @JackHeald5Learn more:Stay Off My Operating Table on AmazonTake Dr. Ovadia's metabolic health quiz: iFixHearts Dr. Ovadia's website: Ovadia Heart HealthJack Heald's website: CultYourBrand.comTheme Song : Rage AgainstWritten & Performed by Logan Gritton & Colin Gailey(c) 2016 Mercury Retro RecordingsAny use of this intellectual property for text and data mining or computational analysis including as training material for artificial intelligence systems is strictly prohibited without express written consent from Dr. Philip Ovadia.

JAMA Medical News Director Jennifer Abbasi and Associate Managing Editor Kate Schweitzer discuss "What to Know About the New Lipid Guidelines." Related Content: What to Know About the New Lipid Guidelines

In this week's episode of the Blood podcast, editor Dr. James Griffin interviews Drs. Christian Gorzelanny and Rebecca Leaf on their latest articles published in this week's issue of Blood. Dr. Gorzelanny discusses compelling evidence for a new mechanism that amplifies their proinflammatory actions in "Lipid nanotubes unmask neutrophils for complement attack", demonstrating the pathological role of this process in a range of inflammatory disorders in order to stimulate intense study of how to regulate nanotube formation for therapeutic benefit. In "Immune thrombocytopenia in patients treated with immune checkpoint inhibitors" Dr. Leaf and colleagues define the incidence, clinical features, and outcomes of ICI-induced immune thrombocytopenia. Showing that ICI-induced immune thrombocytopenia is associated with excess mortality, these data should provide an impetus to greater recognition and to protocolization of effective interventions.

There is a lot of noise online right now around cholesterol, keto, carnivore, and what actually counts as “healthy” and in this episode, Susan cuts straight through it. She unpacks some of the biggest myths being repeated in the wellness space, explains why high cholesterol should never be brushed off without deeper testing, and shares why a one-size-fits-all approach can do more harm than good.This conversation is a powerful reminder that your body is not a trend. Susan breaks down the connection between lipids, inflammation, insulin resistance, genetics, and cardiovascular risk in a way that actually makes sense. If you've ever been told your labs are “fine,” wondered whether high-fat diets are really safe for everyone, or wanted to better understand what testing actually matters, this episode will leave you thinking differently about your health and how to advocate for it.In this episode:Why high cholesterol on keto or carnivore should not automatically be ignoredThe biggest myths Susan sees around LDL, HDL, and heart healthWhy standard cholesterol panels often miss the full pictureThe difference between LDL particle size, particle number, ApoB, and Lp(a)How inflammation and insulin resistance quietly raise cardiovascular riskWhy genetics can dramatically change how someone responds to high-fat dietsThe key labs and advanced testing Susan recommends asking forWhy personalized health matters more than following the latest diet trendRESOURCES:Stello Glucose Monitorhttps://www.stelo.com/Find all of Susan's Resources and links in the show notes: Shop the products: http://healthygut.com/healthyawakenings (this link will provide you a special discount!)https://healthyawakening.co/2026/03/12/episode115/Connect with Susan: https://healthyawakening.co/Visit the website: healthyawakening.co/podcastFind listening links here: https://healthyawakening.co/linksP.S. Want reminders about episodes? Sign up for our newsletter, you can find the link on our podcast page! https://healthyawakening.co/podcast

In this first deep dive, Leslie Cho explores how lipidology and hormone therapy intersect in women's cardiovascular care. Drawing on major guideline work and trial data, she explains how clinicians should approach menopausal hormone therapy, complex lipid disorders, microvascular disease, and emerging therapies through a precision lens.  Timestamps:  01:10 – Menopausal hormone therapy  03:45 – Lipid-lowering therapy  05:55 – Microvascular disease  07:55 – Testosterone therapy 

Lipids remain central to cardiovascular prevention. The 2026 ACC/AHA Dyslipidemia Guideline introduces several important shifts:   • PREVENT equations replace older ASCVD risk calculators • Lipoprotein(a) measurement recommended at least once in all adults • ApoB helps identify residual lipoprotein risk • Coronary artery calcium scoring refines treatment decisions • LDL-C targets return, with

In this podcast, JPEN Editor-in-Chief Dr. Kenneth Christopher, interviews Dr. Katie Huff from the Division of Neonatology at Cincinnati Children's Hospital Medical Center. Dr. Katie Huff is a clinical researcher in Neonatal nutrition with a specific focus on intestinal failure and intestinal failure-associated liver disease. Dr. Katie Huff is first author of the research article “Developmental outcomes after soybean oil vs mixed‐oil intravenous lipid emulsions in neonates: A secondary analysis of a clinical trial”. Business Corporate by Alex Menco | alexmenco.net Music promoted by www.free-stock-music.com Creative Commons Attribution 3.0 Unported License creativecommons.org/licenses/by/3.0/deed.en_US February 2026

What does over 18 months of precision medicine actually look like in practice? In this episode of the Optispan Success Story Series, Dr. Matt Kaeberlein sits down with Carlos Pinto, a tech executive and early Optispan client, to trace his longitudinal health journey from metabolic warning signs to measurable, sustained transformation. Carlos shares how a decade of overlooked biomarkers, a post-pandemic health decline, and a single panic attack became the catalyst for a data-driven approach to his own biology. Together, he and Dr. Kaeberlein review real DEXA, lipid, metabolic, and environmental biomarker data, unpacking what moved the needle, what didn't, and why the answer was rarely simple. This conversation is a candid look at what it means to become your own best health advocate, not through quick fixes, but through personalized, longitudinal learning.Timestamps:0:00 – Cold open & highlights0:50 – Welcome & Carlos's background in tech leadership2:15 – How career ambition displaced health in his 20s and 30s3:39 – A panic attack as the turning point: connecting mental and physical health4:24 – A previous medical wellness program: what worked and what was missing6:34 – Arriving at OptiSpan: intention, mindset, and expectations7:15 – Gateway Day: comprehensive baseline testing and initial surprises8:51 – Early metabolic lessons: CGM data, glucose spikes, and dawn effect11:32 – Confronting white coat hypertension with 78 data points13:28 – How stress, sleep, and nutrition interact to drive metabolic dysfunction15:44 – Personal experimentation as methodology: berberine, time-restricted eating, and fish17:09 – Mercury toxicity from fish consumption: a case study in biomarker surveillance18:33 – Stress management protocols: walking, meditation, and measurable outcomes19:49 – Statin introduction: the role of medication as a tool, not a failure20:27 – DEXA results: visceral fat reduction, body fat loss, and lean mass gain24:17 – Lipid profile transformation: ApoB from ~115 to 70, LDL from 160 to 7425:57 – A1C trajectory and the complexity of glucose optimization30:01 – Reframing medication: proactive use vs. reactive disease management31:29 – Mercury biomarker deep dive: from 2.4 to 16 and back to 232:21 – Goals for the future: sustainability, muscle retention, and mental clarity36:30 – Lineage biological age algorithm: from mortality risk of 54 to 5239:27 – Closing reflections: health as a lifelong trajectory, not a program

Discover why cotton candy can beat a corn dog, how the perimeter-of-the-store hack simplifies everything, and what it really looks like to eat like your great-grandparents. Episode Summary In part 3 of the “Ancestral Mismatch” series, Ben Greenfield delivers three no-nonsense dietary strategies that anyone can implement without breaking the bank or setting foot in an overpriced health food store. You'll learn why fried seed oils are more damaging than sugar (and why Ben would choose cotton candy over a corn dog every time), how to avoid ultra-processed foods by shopping the perimeter of any grocery store, and why sourcing your food matters for your health, animal welfare, and the planet. Ben even drops his go-to travel grocery list that works at any supermarket on Earth. Question of the Day

Autism, Parenting, And The Art Of Ignoring Unsolicited Advice Julie Green had a very limited understanding of autism before her son was born. Navigating his diagnosis was difficult, especially when differing opinions were being thrown at them from all sides. Green reveals the realities of motherhood, autism, and self-discovery in her new book, Motherness. Guests: Julie M. Green, author, Motherness Host: Elizabeth Westfield Producer: Kristen Farrah     Kitchen Chemistry: The Cooking Oil That May Be Driving Obesity Though there are various cooking oils to choose from, soybean oil remains the most commercially popular choice in America. But is this cheap option making us obese? Our experts reveal how the high concentration of a particular fatty acid in this common oil may be influencing how our bodies store fat and contribute to rising health concerns. Guests:  Sonia P. Deol, assistant professional researcher in the department of microbiology and plant pathology, University of California, Riverside Frances M. Sladek, professor of cell biology & toxicologist, University of California, Riverside Host: Greg Johnson Producer:  Kristen Farrah   Medical Notes: How Energy Drinks May Worsen Your Cancer, A Non-Invasive Treatment For Seizures, And How To Fight Against Procrastination   Are energy drinks making you sick? A new treatment for seizures may soon be possible without the need for invasive brain surgery. Good news for sugar addicts! Scientists have created a healthier sweetener using tagatose. How to fight against procrastination. Host: Maayan Voss de Bettancourt Producer: Kristen Farrah Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Kitchen Chemistry: The Cooking Oil That May Be Driving ObesityThough there are various cooking oils to choose from, soybean oil remains the most commercially popular choice in America. But is this cheap option making us obese? Our experts reveal how the high concentration of a particular fatty acid in this common oil may be influencing how our bodies store fat and contribute to rising health concerns.Guests: Sonia P. Deol, assistant professional researcher in the department of microbiology and plant pathology, University of California, RiversideFrances M. Sladek, professor of cell biology & toxicologist, University of California, RiversideHost: Greg JohnsonProducers: Kristen Farrah Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Key TakeawaysHow does the precise localization of GPCRs in lipid rafts reshape drug discovery strategy? Examine implications for functional assays and therapeutic innovation.Explore the pivotal role of GPCR-lipid raft compartmentalization in receptor signaling, desensitization, and pharmacology research. Dr. Keyvan Sedaghat discusses assay approaches, regulatory mechanisms, and the translational impact of bitter taste receptors beyond sensory biology. Leveraging decades of experience in assay development and database creation, he offers actionable insights for researchers optimizing GPCR drug discovery pipelines.Compartmentalization of GPCRs in lipid rafts directly influences receptor signaling and drug response.Desensitization pathways of dopamine D1 receptors depend on precise phosphorylation domains—challenging classical paradigms.Bitter taste receptors demonstrate functional relevance in non-gustatory tissues with emerging therapeutic applications.Database-driven research accelerates the identification of receptor-microdomain interactions for novel targets.Integration of computational modeling and biochemical validation is essential for advancing GPCR assay strategies.Dr. GPCR Links & ResourcesAccess the Dr. GPCR Ecosystem at https://www.ecosystem.drgpcr.com/ for community, tools, and databases.Details on Membership & Pricing: https://www.ecosystem.drgpcr.com/university-pricingGPCR Weekly News: https://www.ecosystem.drgpcr.com/gpcr-weekly-newsExplore Dr. GPCR Premium for expanded translational resources and networking.About the GuestDr. Keyvan Sedaghat holds a pharmacy degree and a PhD in cellular and molecular medicine, specializing in pharmacology, from the University of Ottawa. With over two decades of academic experience, he has served as a professor, senior lecturer, and chief scientific officer in the pharmaceutical and cosmetic industries. Dr. Sedaghat's work spans peer-reviewed publications and editorial roles across journals in molecular pharmacology, cell signaling, and G protein-coupled receptors. His scientific drive centers on unraveling molecular mechanisms underlying GPCR function and translating those findings into effective teaching, research, and drug discovery strategies.Guest on the Web:LinkedInGoogle Scholar

Today, I am excited to share the first class in a series of lipid masterclasses with the amazing Dr. Thomas Dayspring! Dr. Dayspring is certified in internal medicine and clinical epidemiology and is a fellow of the American College of Physicians and the National Lipid Association. He was previously the Educational Director of a nonprofit organization and has served as the Chief Academic Advisor for two major cardiovascular labs.  Given the in-depth nature of my discussions with Dr. Dayspring over several sessions, each lasting nearly six hours, it seemed logical to present these masterclasses in segments to make them easier to understand. In our first class today, we dive into the fundamentals, exploring what lipids are and how lipids and fatty acids are classified. We cover the physiology and transport of cholesterol and the roles of apoptosis, apo-proteins, and apo-lipoproteins; we unravel the differences between HDL, LDL, IDL, and VLDL; and we explain how to calculate LDL and triglycerides to assess metabolic health. Dr. Dayspring also shares his preferences regarding lab values and indicators that help him assess the early risk of cardiovascular disease. We cover some detailed aspects of physical chemistry in this episode, so I highlight the main clinical points throughout our conversation to make it easier to follow. Be sure to join Dr. Dayspring and me for our next episode in the lipid masterclass series. IN THIS EPISODE YOU WILL LEARN: What are lipids, and why are they important? Dr. Dayspring explains what triglycerides are. How lipids get absorbed and transported throughout the body What lipoproteins are, and how they get classified How cholesterols get calculated The impact of triglycerides on cholesterol levels and cardiovascular health How high triglyceride levels can indicate early insulin resistance or increased ASCVD risk What is the role of HDL particles? How metabolic syndrome impacts cardiovascular health Bio: Thomas Dayspring MD is a Fellow of both the American College of Physicians and the National Lipid Association and is certified in internal medicine and clinical lipidology. After practicing in New Jersey for 37 years, he moved to Virginia in 2012. He served as an educational director for a nonprofit cardiovascular foundation and, until mid-2019, as a Chief Academic Advisor for two major CV laboratories. Since then, he has served as a virtual cardiovascular / lipidology educator. Career-wise he has given over 4000 domestic (in all 50 states) and several international lectures, including over 600 CME programs on atherothrombosis, lipids/lipoproteins (and their treatment), vascular biology, biomarker testing, and women's cardiovascular issues. He has authored several manuscripts and lipid textbook chapters and performed several podcasts. For several years, he was an Associate Editor of the Journal of Clinical Lipidology. He was the recipient of the 2011 National Lipid Association's Presidents Award for services to clinical lipidology and the 2023 Foundation of NLA Clinician/Educator Award. He has over 34K followers on his educational Twitter (X) feed (@Drlipid). He has Gold Heart Member status as a professional member of the American Heart Association and serves as a Social Media Ambassador for the European Atherosclerosis Society and the National Lipid Association. Connect with Cynthia Thurlow Follow on X, Instagram & LinkedIn Check out Cynthia's website Submit your questions to support@cynthiathurlow.com Join other like-minded women in a supportive, nurturing community (The Midlife Pause/Cynthia Thurlow)  Cynthia's Menopause Gut Book is on presale now! Cynthia's Intermittent Fasting Transformation Book The Midlife Pause supplement line Connect with Dr. Thomas Dayspring ⁠Twitter⁠ (@DrLipid) ⁠LinkedIn⁠ ⁠Books written by Gary Taubes⁠ 

Contributor: Alec Coston, MD Educational Pearls: Disclaimer: this has nothing to do with the ER but is too cool to not talk about. Condition: Carbamoyl phosphate synthetase 1 (CPS1) deficiency Rare inborn error of metabolism Inability to properly break down ammonia Leads to severe hyperammonemia and hepatic encephalopathy Natural history: Without treatment, typically fatal within the first few weeks of life Even with current standard treatments, life expectancy is often limited to ~5–6 years Breakthrough treatment: A team of researchers at the Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania developed the CRISPR-based targeted gene therapy for this patient. First-of-its-kind precision approach tailored to the patient's specific mutation Key components of the therapy: Whole-genome sequencing to identify the exact CPS1 mutation Creation of a custom base-editing enzyme designed to correct that specific mutation Design of a guide RNA to direct the base editor to the precise genomic location Delivery method: Lipid nanoparticles used to deliver the gene-editing machinery Nanoparticles can be targeted to specific tissues Why the liver works well: CPS1 is primarily expressed in hepatocytes The liver is relatively easy to target with lipid nanoparticles Hepatocytes divide frequently, allowing edited genes to be passed on as cells replicate Long-term impact: Once edited, cells continue producing functional CPS1 enzyme Potential for durable, possibly lifelong correction from a single treatment References https://www.nih.gov/news-events/news-releases/infant-rare-incurable-disease-first-successfully-receive-personalized-gene-therapy-treatment Choi Y, Oh A, Lee Y, Kim GH, Choi JH, Yoo HW, Lee BH. Unfavorable clinical outcomes in patients with carbamoyl phosphate synthetase 1 deficiency. Clin Chim Acta. 2022 Feb 1;526:55-61. doi: 10.1016/j.cca.2021.11.029. Epub 2021 Dec 29. PMID: 34973183. Bharti N, Modi U, Bhatia D, Solanki R. Engineering delivery platforms for CRISPR-Cas and their applications in healthcare, agriculture and beyond. Nanoscale Adv. 2026 Jan 5. doi: 10.1039/d5na00535c. Epub ahead of print. PMID: 41640466; PMCID: PMC12865601. Summarized and edited by Jeffrey Olson MS4 Donate: https://emergencymedicalminute.org/donate/ Join our mailing list: http://eepurl.com/c9ouHf

Artificial intelligence is rapidly changing how we understand our health — not just how we feel today, but how fast we're actually aging.On this episode of Live Long, host Peter Bowes continues his personal experiment with Hundred, the AI-powered longevity platform that combines advanced blood testing, wearable data and personalized insights to track biological age and guide smarter health decisions.After introducing the app in an earlier conversation, Peter reconnects with Hundred's founder, Tyler Smith, to go deeper into the idea of a “health operating system” — essentially a personal doctor in your pocket. Together they explore how continuous testing and AI analysis could help prevent disease, spot risks earlier, and motivate lasting behavior change — while also addressing the realities of over-testing, false alarms, privacy concerns and health anxiety.Peter also shares the results of his own first round of testing, what surprised him most, and how he's using the data to shape his approach to longevity and healthy aging.-----JOIN HUNDREDOptimize your healthspan and potentially lower your biological age.  Tyler and the team at HUNDRED are offering $75 in credit for add-on tests and supplements from the HUNDRED marketplace when you sign up at hundred.com/livelongpodcastThis podcast is supported by affiliate arrangements with a select number of companies. We have arranged discounts on certain products and receive a small commission on sales. The income helps to cover production costs and ensures that our interviews remain free for all to listen. Visit our SHOP for more details: https://healthspan-media.com/live-long-podcast/shop/Time-line Mitopure (a highly pure form of Urolithin A) boosts the health of our mitochondria – the battery packs of our cells – and improves muscle strength. Time-line is offering LLAMA listeners a 10% discount on its range of products – Mitopure powders, softgels & skin creams.  Use the code LLAMA at checkout-Fit, Healthy & Happy Podcast Welcome to the Fit, Healthy and Happy Podcast hosted by Josh and Kyle from Colossus...Listen on: Apple Podcasts SpotifyEnergyBits algae snacksA microscopic form of life that could help us age better. Use code LLAMA for a 20 percent discountPartiQlar supplementsEnhance your wellness journey with pure single ingredients. 15% DISCOUNT - use code: MASTERAGING15Disclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.Support the showThe Live Long and Master Aging (LLAMA) podcast, a HealthSpan Media LLC production, shares ideas but does not offer medical advice. If you have health concerns of any kind, or you are considering adopting a new diet or exercise regime, you should consult your doctor.

We have another short-form, live YouTube episode today, where I dive into questions from listeners. Recently, the most frequently asked questions have been about cholesterol, likely because I often reference my podcast series with Dr. Tom Dayspring, a renowned lipidologist and menopause expert. Join me today to clear away some more of the confusion surrounding cholesterol. IN THIS EPISODE, YOU WILL LEARN: Why comprehensive lipid testing rather than standard testing is essential, post-menopause How menopause impacts women's lipid and triglyceride levels The roles APO B and Lp(a) play in assessing cardiac risk How the cardiac risk of women increases as estrogen declines The cardiac health benefits of monitoring lipids and considering HRT within the first six years of menopause What research studies reveal about how menopause influences cardiovascular risk Connect with Cynthia Thurlow   Follow on X, Instagram & LinkedIn Check out Cynthia's website Submit your questions to support@cynthiathurlow.com Join other like-minded women in a supportive, nurturing community: The Midlife Pause/Cynthia Thurlow  Cynthia's Menopause Gut Book is on presale now! Cynthia's Intermittent Fasting Transformation Book The Midlife Pause Supplement Line Episodes with Dr. Thomas Dayspring: Episode 336: Lipid Masterclass: An Introduction to Lipids and Cholesterol with Dr. Thomas Dayspring Episode 344: Lipid Masterclass: A Deep Dive into Our Cardiovascular Needs with Thomas Dayspring Episode 352: Lipid Masterclass: Apo-B, Labs and Women's Heart Health with Thomas Dayspring Episode 495: Are You At Risk for Dementia? – The Most Overlooked Cholesterol Marker You Need to Know with Dr. Thomas Dayspring

Dr. Jessica Rose, PhD, MSc, BSc, is a Senior Fellow specializing in Computational Biology from Canada. She holds a Bachelor's Degree in applied mathematics and a master's degree in Immunology from Memorial University of Newfoundland, and a PhD in Computational Biology from Bar Ilan University. Dr. Rose has completed two post-doctoral degrees in Molecular Biology from the Hebrew University of Jerusalem, and in Biochemistry from the Technion Institute of Technology. She is best known for her contributions to public health and safety related to the COVID-19 injectable products, and her analyses of pharmacovigilance databases like VAERS. In this episode, Drs. Brian and Jessica talk about… (00:00) Intro (04:57) Dr. Jessica's upbringing, personality, and scientific pursuits (09:41) Covid vaccines, natural immunity, and bodily autonomy of individuals (19:50) The research of Kevin McKernan on DNA in vials of COVID-19 vaccines (27:39) The composition and production of Covid mRNA vaccines (33:04) National health regulation agencies and Covid vaccine DNA contamination (35:54) Lipid nanoparticles in mRNA vaccines and how they impact human health (44:22) Vaccine injuries due to spike protein proliferation and how the spike protein ruins the human immune system (54:38) Spike protein detox therapies (01:01:12) Fascia release (01:03:07) Cholesterol, gal bladder health, and nutrition (01:07:54) Fasting, autophogy, and the microbiome (01:11:33) Peer review and post-peer review attacks on valid research (01:21:53) Outro   For more information, please see the links below. Thank you for listening!   Links:   Resources Mentioned in this Episode: Jules Horn (Fascia Release): https://www.youtube.com/@Jules_horn Science Guardians (post-peer review group): https://x.com/SciGuardians   Dr. Jessica Rose: Research: https://www.researchgate.net/profile/Jessica-Rose-24 Why does DNA remain in vials of COVID-19 mRNA Shots?: https://rumble.com/v74rdvs-why-does-dna-remain-in-vials-of-covid-19-mrna-shots.html What Jessica Rose Knows: Dr. Jessica Rose on DarkHorse: https://rumble.com/v5q0zl8-what-jessica-rose-knows-dr.-jessica-rose-on-darkhorse.html   Dr. Brian Lenzkes:  Arizona Metabolic Health: https://arizonametabolichealth.com/ Low Carb MD Podcast: https://www.lowcarbmd.com/   HLTH Code: HLTH Code Promo Code: METHEALTH • • HLTH Code Website: https://gethlth.com

In this episode of The Brainstorm, we delve into the groundbreaking advancements in gene editing, focusing on its potential to transform healthcare. We explore the shift from treating rare diseases to tackling common killers like cardiovascular disease, and discover how CRISPR technology is paving the way for a new era in medical treatment.If you know ARK, then you probably know about our long-term research projections, like estimating where we will be 5-10 years from now! But just because we are long-term investors, doesn't mean we don't have strong views and opinions on breaking news. In fact, we discuss and debate this every day. So now we're sharing some of these internal discussions with you in our new video series, “The Brainstorm”, a co-production from ARK and Wolf.financial, and sponsored by Public. Tune in every week as we react to the latest in innovation. Here and there we'll be joined by special guests, but ultimately this is our chance to join the conversation and share ARK's quick takes on what's going on in tech today.Key Points From This Episode:CRISPR-based gene editing is moving from treating rare diseases to addressing common conditions like cardiovascular disease.The transition from ex vivo to in vivo gene editing could simplify treatment processes significantly.Lipid nanoparticle delivery is a key advancement enabling in vivo gene editing.The potential market for in vivo gene editing treatments is vast, with significant implications for healthcare costs and patient outcomes.To learn more about WOLF: https://wolf.financialTo learn more about Public: https://public.com/Relevant Links:https://www.ark-invest.com/newsletters/issue-491

Master cardiovascular disease prevention! Learn how to apply the new PREVENT risk calculator, use the CPR framework for risk reclassification, and interpret ApoB and Lp(a) in modern lipid management. We're joined by Dr. Laurence Sperling to break down what's new in ASCVD risk assessment and prevention. Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments Intro Case 1 from Kashlak  Risk assessment framework ApoB and Non-HDL cholesterol Lipoprotein(a) and its importance The PREVENT risk score and its implications Statins and other lipid lowering therapies The role of diet and lifestyle in lipid management Case 2 from Kashlak Familial Hypercholesterolemia diagnosis and management Key takeaways Outro Credits Producer, Writer, Shownotes, Infographic, and Cover art: Ben Furman, MPH  Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Leah Witt, MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Laurence Sperling, MD  Disclosures Dr. Sperling reports no relevant financial disclosures. The Curbsiders report no relevant financial disclosures. Sponsor: Bucksbaum-Siegler Institute If you want to learn more about what the Bucksbaum-Siegler Institute is doing and to nominate someone for the Clinical Excellence Award—you can check them out today. Visit bucksbauminstitute.uchicago.edu. Sponsor: Grammarly  Sign up for FREE and experience how Grammarly can elevate your professional writing from start to finish. Visit Grammarly.com/podcast.  Sponsor: Continuing Education Company Use promo code Curb30 to get 30% off all online courses and webcast. Visit CMEmeeting.org/curbsiders to learn more. Sponsor: Freed Use code: CURB50 to get $50 off your first month when you subscribe!

I am honored to have Dr. Tom Dayspring join me again today for another AMA session. He and I have done eight podcasts before, and this is a continuation of our last Ask Me Anything episode.  Dr Dayspring is an esteemed expert on internal medicine and clinical lipidology. He is likely one of the most influential worldwide lipid experts, so I am thrilled to have him back with me to dive into various topics related to listener questions, including the impact of hormone replacement therapy on lipid changes, methods of administration, and why bioidentical hormone replacement therapy is preferable for managing both menopausal symptoms and lipid health. We discuss medications, including PCSK9 inhibitors and GLP-1s, as well as intermittent fasting, lipids, and cardiovascular disease risk. We also examine how heart disease develops gradually, over time, the impact of stress and lifestyle, and Dr. Dayspring shares the labs he recommends beyond traditional lipids, ApoB, and LpA. In our discussion, Dr. Dayspring noted that he was not in a position to speak about GLP-1 therapies or microdosing. Since I received many questions from listeners on those topics, I will host a future solo AMA to address some of their concerns. Today's conversation with Dr. Tom Dayspring is truly invaluable, and I trust you will walk away with valuable insights you can share with your healthcare providers. We created a PDF - cynthiathurlow.com/lipids -  specifically for listeners that outlines key labs to discuss with your providers and questions to ask them to help you advocate for your own health and your family members' health. IN THIS EPISODE, YOU WILL LEARN: Why being physically fit does not always eliminate the risk of heart problems arising How ApoB and cholesterol contribute to heart disease over decades Why the early testing of risk factors is essential How chronic stress increases the risk of heart disease  How high cortisol affects insulin sensitivity and glucose regulation How stress impacts endothelial and nitric oxide function The link between low Omega-3 levels and heart problems How insulin resistance degrades heart health How high homocysteine levels can impair endothelial function and contribute to cardiovascular problems Connect with Cynthia Thurlow   Follow on⁠ X⁠,⁠ Instagram⁠ &⁠ LinkedIn⁠ Check out Cynthia's⁠ website⁠ Submit your questions to support@cynthiathurlow.com Join other like-minded women in a supportive, nurturing community ⁠(The Midlife Pause/Cynthia Thurlow⁠)⁠ ⁠ Cynthia's⁠ Menopause Gut Book⁠ is on presale now! Cynthia's⁠ Intermittent Fasting Transformation⁠ Book ⁠The Midlife Pause supplement line⁠ Connect with Dr. Thomas Dayspring On X (@DrLipid) On LinkedIn